Allergan Reports Settlement On RESTASIS 0.05% Patent Litigation With InnoPharma

(RTTNews) - Allergan plc (AGN) said that it has reached an agreement with InnoPharma Inc. resolving patent litigation regarding United States Patent Nos. 8,629,111; 8,633,162; 8,642,556; 8,648,048; 8,685,930 and 9,248,191 covering RESTASIS (Cyclosporine Ophthalmic Emulsion) 0.05%. The patents are listed in the Orange Book and expire on August 27, 2024.

As a result of the settlement, all InnoPharma Hatch-Waxman litigation regarding RESTASIS patents will be dismissed.

As per to the terms of the settlement, Allergan will grant InnoPharma licenses to market a generic version of RESTASIS in the United States beginning on February 24, 2024, or earlier under certain circumstances.

Additionally, under certain circumstances, Allergan will supply and authorize InnoPharma to launch an authorized generic version of RESTASIS on August 28, 2024. Additional details regarding the settlement were not disclosed.